PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH)Kiel, Germany, January 8, 2025 – tiakis ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Cibotercept is under clinical development by Keros Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension.

Many roadblocks exist to detecting and assessing pulmonary hypertension (PH) in patients with interstitial lung disease (ILD), but creative thinking and artificial intelligence (AI) may soon help ...